Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

21 mai 2024 20h05 HE | Source: Robbins LLP

June 4th Lead Plaintiff Deadline Approaching in Class Action Against Checkpoint Therapeutics, Inc. – Contact Robbins LLP Today

Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab
26 avr. 2024 16h56 HE | Source: Robbins LLP

Robbins LLP Reminds Stockholders of CKPT to Contact the Law Firm for Information About the Checkpoint Therapeutics, Inc. Class Action Lawsuit

Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab
15 avr. 2024 17h14 HE | Source: Robbins LLP

CKPT Class Action Alert: Robbins LLP Reminds Stockholders of Checkpoint Therapeutics, Inc. Class Action

Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab
10 avr. 2024 17h52 HE | Source: Portnoy Law

Checkpoint Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; June 4, 2024 deadline.

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 10, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Checkpoint Therapeutics, Inc....
07 avr. 2024 23h21 HE | Source: Robbins LLP

Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against Checkpoint Therapeutics, Inc. (CKPT)

Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab